Anika Therapeutics (ANIK) Receivables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Receivables data on file, last reported at $25.8 million in Q1 2026.

• On a quarterly basis, Receivables rose 17.2% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $25.8 million, a 17.2% increase from a year earlier, with the FY2025 full-year figure at $23.7 million, changed 0.41% from the prior year.
• Receivables for Q1 2026 stood at $25.8 million, up from $23.7 million in the prior quarter.
• Over the last five years, Receivables for ANIK reached as high as $38.4 million in Q2 2023 and fell as low as $22.0 million in Q1 2025.
• Historically, Receivables has averaged $29.0 million across 5 years, with a median of $27.7 million in 2023.
• Across the five-year window, Receivables tumbled 31.46% in 2025 and gained 17.2% in 2026, its largest moves.
• Year by year, Receivables stood at $36.2 million in 2022, then slipped by 25.41% to $27.0 million in 2023, then slipped by 12.7% to $23.6 million in 2024, then increased by 0.41% to $23.7 million in 2025, then rose by 8.77% to $25.8 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $25.8 million in Q1 2026, $23.7 million in Q4 2025, and $23.1 million in Q3 2025.